Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19.

ABSTRACT:

Background

Metabolic diseases are risk factors for severe Coronavirus disease (COVID-19), which have a close relationship with metabolic dysfunction-associated fatty liver disease (MAFLD).

Aims

To evaluate the presence of MAFLD and fibrosis in patients with COVID-19 and its association with prognosis.

Methods

Retrospective cohort study. In hospitalized patients with COVID-19, the presence of liver steatosis was determined by computed tomography scan (CT). Liver fibrosis was assessed using the NAFLD fibrosis score (NFS score), and when altered, the AST to platelet ratio index (APRI) score. Mann-Whitney U, Student´s t-test, logistic regression analysis, Kaplan-Meier curves and Cox regression analysis were used.

Results

432 patients were analyzed, finding steatosi

SUBMITTER: Campos-Murguia A 

PROVIDER: S-EPMC8047402 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature